Logo image of NTHI

NEONC TECHNOLOGIES HOLDINGS (NTHI) Stock Fundamental Analysis

NASDAQ:NTHI - Nasdaq - US64051A1016 - Common Stock - Currency: USD

3.72  +0.02 (+0.54%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NTHI. NTHI was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NTHI have multiple concerns. NTHI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NTHI has reported negative net income.
NTHI Yearly Net Income VS EBIT VS OCF VS FCFNTHI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M

1.2 Ratios

With a Return On Assets value of -591.12%, NTHI is not doing good in the industry: 96.41% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -591.12%
ROE N/A
ROIC N/A
ROA(3y)-648.49%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NTHI Yearly ROA, ROE, ROICNTHI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 67.48%, NTHI is in the better half of the industry, outperforming 74.36% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for NTHI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTHI Yearly Profit, Operating, Gross MarginsNTHI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

NTHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTHI has about the same amout of shares outstanding than it did 1 year ago.
NTHI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NTHI Yearly Shares OutstandingNTHI Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
NTHI Yearly Total Debt VS Total AssetsNTHI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M

2.2 Solvency

NTHI has an Altman-Z score of -31.32. This is a bad value and indicates that NTHI is not financially healthy and even has some risk of bankruptcy.
NTHI has a worse Altman-Z score (-31.32) than 85.13% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.32
ROIC/WACCN/A
WACC9.69%
NTHI Yearly LT Debt VS Equity VS FCFNTHI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 -2M -4M -6M -8M -10M

2.3 Liquidity

NTHI has a Current Ratio of 0.41. This is a bad value and indicates that NTHI is not financially healthy enough and could expect problems in meeting its short term obligations.
NTHI's Current ratio of 0.41 is on the low side compared to the rest of the industry. NTHI is outperformed by 93.85% of its industry peers.
NTHI has a Quick Ratio of 0.41. This is a bad value and indicates that NTHI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.41, NTHI is doing worse than 92.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.41
NTHI Yearly Current Assets VS Current LiabilitesNTHI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.26% over the past year.
The Revenue has grown by 17.73% in the past year. This is quite good.
EPS 1Y (TTM)20.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)17.73%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NTHI Yearly Revenue VS EstimatesNTHI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 20K 40K 60K 80K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTHI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTHI Price Earnings VS Forward Price EarningsNTHI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTHI Per share dataNTHI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTHI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEONC TECHNOLOGIES HOLDINGS

NASDAQ:NTHI (6/25/2025, 8:00:02 PM)

3.72

+0.02 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.31%
Inst Owner ChangeN/A
Ins Owners25.48%
Ins Owner Change5.24%
Market Cap70.79M
AnalystsN/A
Price TargetN/A
Short Float %0.29%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 575.54
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.73
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.01
BVpS-0.51
TBVpS-0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -591.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.48%
FCFM N/A
ROA(3y)-648.49%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.41
Altman-Z -31.32
F-ScoreN/A
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.73%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-124.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.14%
OCF growth 3YN/A
OCF growth 5YN/A